In vivo delivery of plasmid DNA expression vectors has shown to be an efficient means of inducing an immune response against the expressed gene sequence. Stimulating host immune responses against tumors using this method is an attractive cancer therapy approach. The effectiveness of genetic immunotherapy will depend on the properties of the tumor-associated antigen (TAA) used to induce the anti-tumor immune response, as well as the site and level of TAA expression. Mirus? intravascular non-viral gene delivery techniques have shown especially efficient at inducing transgene-directed immune responses, due to the types of cells that are transfected (including antigen presenting cells) and the high levels of expression that are obtained. The main Aim of this grant proposal is to use these proven highly efficient gene transfer techniques to evaluate TAAs in relevant in vivo tumor models, and to select novel TAAs from human tumor expression libraries. In Phase I, we will determine if these in vivo non-viral gene transfer techniques result in prophylactic and therapeutic anti-tumor immune responses in the B16 murine melanoma model. In parallel, we will determine the optimal genetic vaccination conditions (e.g., co-delivery of cytokine genes, minimal amount of pDNA required). In Phase II, subtracted expression libraries will be constructed from human tumor cells. TAA genes in the library that illicit anti-tumor responses will be selected by transferring individual clones or (partial) libraries into mice, followed by tumor challenge. Through successive rounds, specific and highly active TAAs will be isolated. Successful selection and evaluation of novel TAAs can be performed because of the very efficient immune response obtained following Mirus? intravascular gene delivery techniques, which can also be used to deliver TAAs to cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA095929-01
Application #
6479231
Study Section
Special Emphasis Panel (ZCA1-SRRB-U (J2))
Program Officer
Muszynski, Karen
Project Start
2002-09-26
Project End
2004-08-31
Budget Start
2002-09-26
Budget End
2003-08-31
Support Year
1
Fiscal Year
2002
Total Cost
$245,233
Indirect Cost
Name
Mirus Bio Corporation
Department
Type
DUNS #
937904944
City
Madison
State
WI
Country
United States
Zip Code
53711
Lebwohl, Benjamin; Kastrinos, Fay; Glick, Michael et al. (2011) The impact of suboptimal bowel preparation on adenoma miss rates and the factors associated with early repeat colonoscopy. Gastrointest Endosc 73:1207-14
Lebwohl, Benjamin; Neugut, Alfred I; Stavsky, Eliezer et al. (2011) Effect of a patient navigator program on the volume and quality of colonoscopy. J Clin Gastroenterol 45:e47-53
Richards, Catherine A; Kerker, Bonnie D; Thorpe, Lorna et al. (2011) Increased screening colonoscopy rates and reduced racial disparities in the New York Citywide campaign: an urban model. Am J Gastroenterol 106:1880-6
Li, Ke; He, Wei; Lin, Na et al. (2010) Downregulation of N-cadherin expression inhibits invasiveness, arrests cell cycle and induces cell apoptosis in esophageal squamous cell carcinoma. Cancer Invest 28:479-86
Lebwohl, B; Stavsky, E; Neugut, A I et al. (2010) Risk of colorectal adenomas in patients with coeliac disease. Aliment Pharmacol Ther 32:1037-43
McBride, Russell B; Lebwohl, Benjamin; Hershman, Dawn L et al. (2010) Impact of socioeconomic status on extent of lymph node dissection for colon cancer. Cancer Epidemiol Biomarkers Prev 19:738-45
Lebwohl, Benjamin; Ballas, Leslie; Cao, Yin et al. (2010) Treatment interruption and discontinuation in radiotherapy for rectal cancer. Cancer Invest 28:289-94
Neugut, Alfred I; Lebwohl, Benjamin (2010) Colonoscopy vs sigmoidoscopy screening: getting it right. JAMA 304:461-2
Lebwohl, Benjamin; Wang, Timothy C; Neugut, Alfred I (2010) Socioeconomic and other predictors of colonoscopy preparation quality. Dig Dis Sci 55:2014-20
Neugut, Alfred I; Lebwohl, Benjamin (2009) Screening for colorectal cancer: the glass is half full. Am J Public Health 99:592-4